Syrigou Ekaterini, Makrilia Nektaria, Koti Ioanna, Saif Muhammad W, Syrigos Kostas N
Oncology Unit, 3rd Department of Medicine, Athens School of Medicine, Sotiria General Hospital, Athens, Greece.
Anticancer Drugs. 2009 Jan;20(1):1-6. doi: 10.1097/CAD.0b013e32831961b3.
Hypersensitivity reactions to antineoplastic agents are defined as unexpected reactions with signs and symptoms inconsistent with known toxicity of antineoplastic drugs. These reactions are uncommon and usually associated with certain antineoplastic categories, such as taxanes, platinum-containing compounds, epipodofyllotoxins, asparaginase, procarbazine and, more rarely, with doxorubicin and 6-mercaptopurine. The mechanisms that are responsible for hypersensitivity reactions are unclear and vary between agents. Symptoms of these reactions range from mild skin rashes to more severe reactions, such as arthralgia, respiratory arrest or even death in some cases. Once hypersensitivity reactions are observed, basic principles that allow their management and possible continuance and completion of the regimen should be followed.
对抗肿瘤药物的超敏反应被定义为与抗肿瘤药物已知毒性不一致的伴有体征和症状的意外反应。这些反应并不常见，通常与某些抗肿瘤药物类别相关，如紫杉烷类、含铂化合物、表鬼臼毒素、门冬酰胺酶、丙卡巴肼，更罕见的是与阿霉素和6-巯基嘌呤相关。导致超敏反应的机制尚不清楚，且因药物而异。这些反应的症状从轻微的皮疹到更严重的反应，如关节痛、呼吸骤停，在某些情况下甚至死亡。一旦观察到超敏反应，应遵循允许对其进行处理以及可能继续和完成治疗方案的基本原则。
